Health Technology Center for Commercialization—Infrastructure, Partnerships, and Innovation
Healthcare Innovation | Innovate Better | Innovate Faster
We live in an age of medical miracles. We are mapping the human brain, creating diagnostic tests for diseases old and new, and developing high-impact solutions to society’s most challenging health problems. But before these exciting scientific discoveries can make a difference in our everyday lives, they need to travel the long journey out of the laboratory and into the marketplace, navigating a path of technical, regulatory, and funding hurdles.
This is where VentureWell comes in. At multiple points along the process from lab to market, we help move innovation forward. We use our expertise in government funding and award and contract management, as well as our extensive networks, to provide the infrastructure and support services that advance new ideas and new technologies, speeding processes from years to months, so that we all benefit.
VentureWell helps healthcare innovation happen now.
The VentureWell Impact: RADx® Programs, Blueprint MedTech, and the ARPA-H Investor Catalyst Hub
Navigating Paths from Lab to Market
There are a great many steps that come between an innovation in medical science and the arrival of a product on hospital or pharmacy shelves. Notably, the commercialization process requires a team of vendors and professional services consultants to help companies achieve their goals and bring products to consumers. At VentureWell, we leverage our experience and network to rigorously identify, assess, select, and contract with these individuals, ensuring that the necessary expertise is in place and ready when it is needed. This de-risks new technologies and accelerates the time to market.
We have brought all of this together under the Health Technology Center for Commercialization.
To date, VentureWell has worked with government-funded programs like the Rapid Acceleration of Diagnostics (RADx®) Tech programs, Blueprint MedTech, and the ARPA-H Investor Catalyst Hub. We welcome new partners who work in similar spaces, and who share our core mission and values.
Our Current Portfolio
RADx® Programs
Supporting the Production of Over 7,000,000,000 At-Home COVID-19 Tests and Beyond
The COVID-19 pandemic raised public awareness about the need for rapid health care innovation, especially around the importance of quick, accurate, accessible diagnostic tests. In April 2020, the National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx®) Tech program as a collaboration between the Office of the Director (OD) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB).
VentureWell is proud to be a part of the massive effort, which has resulted in the production of over seven billion at-home COVID-19 tests. In addition, over a dozen new diagnostic technologies have received Emergency Use Authorizations (EUA) from the U.S. Food and Drug Administration (FDA).
We continue to provide infrastructure support to RADx®, contracting with hundreds of consultants and vendors to tackle the challenges of rapid diagnostics development. A process that would previously take years has been shortened to months.
VentureWell’s involvement is not limited to COVID-19, but includes other NIH RADx® Tech-type programs, also known as the Innovation Funnel programs. These programs are accelerating the commercialization of technologies to more accurately diagnose and treat infectious diseases (i.e. Mpox, HIV, HCV), to improve maternal health outcomes, and to screen for cancer.
Blueprint MedTech
Treating Disorders of the Nervous System
The brain and the nervous system have tremendous power: They make us who we are.
As humanity explores the neural pathways that let us move and dream, our ability to create medical devices that diagnose and treat disorders of the central nervous system grows. The NIH Blueprint MedTech Program aims to speed the development of cutting-edge technologies. On the path from lab to market, this program moves neurotechnologies from early-stage development to human-grade prototypes ready for clinical trials.
VentureWell accelerates Blueprint innovator projects by sourcing, managing, and contracting with an experienced network of vendors and consultants to both support product development and de-risk barriers to commercialization.
ARPA-H Investor Catalyst Hub
Developing Solutions to Our Most Challenging Health Problems
By investing in solutions—whether molecular or societal—to our most challenging health problems, the Advanced Research Projects Agency for Health (ARPA-H) aims to transform important areas in medicine for all Americans.
Some healthcare problems are too complex to be solved through traditional research or commercial activity. We need audacious ideas to solve these problems—“Ideas so audacious that people say they just might work only—if only we could try. Well, we’re about to try in a big way.” That’s how President Joe Biden describes ARPA-H. ARPA-H solutions aim to benefit everyone.
ARPA-H is a federal research funding agency that supports transformative biomedical and health breakthroughs to provide big-picture health solutions for all. The Investor Catalyst Hub, part of the nationwide ARPA-H Health Innovation Network (ARPANET-H), connects researchers, entrepreneurs, and investors to accelerate the development of innovative healthcare solutions.
Through the Investor Catalyst Hub, VentureWell supports ARPA-H in navigating the complexities of the business, transition, and regulatory landscapes. We provide resources to help bring game-changing solutions to market. We solve big problems in the health field.